Certuity’s Coherus Oncology CHRS Stock Holding History

Certuity’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,000	Closed	-$235K	–	190
2020 Q1	$235K	Hold	14,000	–	–	0.13%	123
2019 Q4	$252K	Buy	+14,000	New	+$258K	0.12%	136

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Certuity's CHRS Position: Q2 2020 in Review

Certuity sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 14,000 shares — an estimated $235K sold.

Certuity first reported a position in CHRS in Q4 2019 and held it in 2 quarters. The position peaked at $252K in Q4 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Certuity reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Certuity sold 14,000 Coherus Oncology shares in Q2 2020, an estimated $235K.
Certuity first reported a position in Coherus Oncology in Q4 2019 and held it in 2 quarters.
Certuity's Coherus Oncology position peaked at $252K in Q4 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Certuity's 13F filing for Q2 2020, filed 11 Aug 2020.